Back to Search Start Over

Prohibitin, relocated to the front ends, can control the migration directionality of colorectal cancer cells.

Authors :
Ma LL
Shen L
Tong GH
Tang N
Luo Y
Guo LL
Hu CT
Huang YX
Huang G
Jing FY
Liu C
Li ZY
Zhou N
Yan QW
Lei Y
Zhu SJ
Cheng ZQ
Cao GW
Deng YJ
Ding YQ
Source :
Oncotarget [Oncotarget] 2017 Jul 19; Vol. 8 (44), pp. 76340-76356. Date of Electronic Publication: 2017 Jul 19 (Print Publication: 2017).
Publication Year :
2017

Abstract

Directional migration is a cost-effective movement allowing invasion and metastatic spread of cancer cells. Although migration related to cytoskeletal assembly and microenvironmental chemotaxis has been elucidated, little is known about interaction between extracellular and intracellular molecules for controlling the migrational directionality. A polarized expression of prohibitin (PHB) in the front ends of CRC cells favors metastasis and is correlated with poor prognosis for 545 CRC patients. A high level of vascular endothelial growth factor (VEGF) in the interstitial tissue of CRC patients is associated with metastasis. VEGF bound to its receptor, neuropilin-1, can stimulate the activation of cell division cycle 42, which recruits intra-mitochondrial PHB to the front end of a CRC cell. This intracellular relocation of PHB results in the polymerization and reorganization of filament actin extending to the front end of the cell. As a result, the migration directionality of CRC cells is targeted towards VEGF. Together, these findings identify PHB as a key modulator of directional migration of CRC cells and a target for metastasis.<br />Competing Interests: CONFLICTS OF INTEREST No potential conflicts of interest are disclosed.

Details

Language :
English
ISSN :
1949-2553
Volume :
8
Issue :
44
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
29100316
Full Text :
https://doi.org/10.18632/oncotarget.19394